Humulin M3 (Mixture 3) (Insulin Human)

Humulin M3 is indicated for the treatment of diabetes mellitus in patients who require both basal and mealtime insulin coverage.

• Type 1 diabetes mellitus requiring mixed insulin therapy.
• Type 2 diabetes mellitus when oral agents and basal insulin are insufficient.
• Adjunct to diet and exercise for glycemic control.
• Use in patients who benefit from a fixed ratio of rapid‑acting and intermediate‑acting insulin.
• Situations where a single daily injection simplifies the regimen.
• Patients transitioning from separate rapid‑acting and intermediate‑acting insulin preparations.

• Humulin M3 binds to insulin receptors on peripheral tissues, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose transporter (GLUT4) translocation to the cell membrane, increasing glucose uptake in muscle and adipose tissue. Simultaneously, hepatic gluconeogenesis and glycogenolysis are suppressed, reducing endogenous glucose production and lowering blood glucose concentrations.

Adverse reactions to Humulin M3 may occur; they are categorized by frequency and severity.

Common

• Hypoglycemia (low blood glucose).
• Injection‑site pain, redness, or swelling.
• Lipodystrophy at injection sites.
• Weight gain.
• Allergic skin reactions such as rash or urticaria.

Serious

• Severe hypoglycemia with loss of consciousness.
• Anaphylactic or systemic allergic reaction.
• Edema or exacerbation of heart failure.
• Persistent hyperglycemia due to insulin resistance.

When prescribing Humulin M3, clinicians should consider several safety factors to minimize risks.

• Risk of hypoglycemia; patients need regular glucose monitoring.
• Adjust dose in renal or hepatic impairment.
• Use with caution in pregnancy; benefits must outweigh potential risks.
• Avoid in patients with known hypersensitivity to human insulin or formulation excipients.
• Store the product according to label to maintain potency.
• Educate patients on proper injection technique and rotation sites.

Humulin M3 can interact with other medicines, affecting blood glucose levels or insulin action.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• Alcohol excess that can precipitate hypoglycemia.
• MAO‑inhibitors that may potentiate insulin effects.

Use with caution

• Thiazide or loop diuretics that may raise blood glucose.
• ACE inhibitors or ARBs that can enhance insulin sensitivity.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) requiring dose coordination.
• Corticosteroids that increase glucose levels.
• Lipid‑lowering agents (e.g., fibrates) that may affect insulin metabolism.